UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 11, 2018
___________________________________
VAREX IMAGING CORPORATION
(Exact name of registrant as specified in its charter)
___________________________________
Delaware
(State or Other Jurisdiction of Incorporation)
|
| | |
| 001-37860 | | 81-3434516 |
| (Commission File Number) | | (IRS Employer Identification No.) |
|
| | |
| 1678 S. Pioneer Road, Salt Lake City, Utah | | 84104 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (801) 972-5000
Not Applicable
(Former name or former address, if changed since last report)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
| |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b - 2 of the Securities Exchange Act of 1934. Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
|
| |
| Item 7.01 | Regulation FD Disclosure |
Management of Varex Imaging Corporation (the “Company”) will use the information in the presentation slides attached hereto as Exhibit 99.1 in meetings with institutional investors, individual investors and analysts at the 2018 J.P. Morgan Healthcare Conference. The attached presentation will be accessible through the “Investors” page of the Company’s website at www.investors.vareximaging.com.
The information included in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 provided pursuant to this Item 7.01, is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended.
|
| |
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
The following exhibit is being furnished, and is not deemed to be filed:
|
| |
| Exhibit No. | Description |
| 99.1 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | |
| | | VAREX IMAGING CORPORATION
|
| | | |
| Dated: January 11, 2018 | By: | /s/ Kimberley E. Honeysett |
| | | Kimberley E. Honeysett |
| | | Senior Vice President, General Counsel and Corporate Secretary |
INDEX TO EXHIBITS
|
| |
| Exhibit No. | Description |
| 99.1 | |
